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Abstract
Background: Up to 70% of nursing home patients with dementia suffer from sleep problems. Light is the main
zeitgeber to the circadian system and thus has a fundamental impact on sleep-wake behaviour. Low indoor light
levels in nursing homes have been reported, and in combination with age-related reductions in light sensitivity,
insufficient light exposure is likely to contribute to sleep problems in this population. Increasing daytime light
exposure using bright light treatment (BLT) may represent a feasible non-pharmacological treatment for sleep
problems in nursing home patients with dementia.
Methods: The present study reports on sleep outcomes, which are the primary outcomes of the DEM.LIGHT trial
(Therapy Light Rooms for Nursing Home Patients with Dementia– Designing Diurnal Conditions for Improved Sleep,
Mood and Behavioural Problems), a 24-week cluster-randomised placebo-controlled trial including 8 nursing home
units and 69 resident patients. The intervention comprised ambient light of 1000 lx and 6000 K from 10:00 to 15:00,
with gradually increasing and decreasing light levels prior to and following this interval, using ceiling mounted
light-fixtures and light emitting diode technology. The placebo condition had continuous standard light levels
(150–300 lx, ~ 3000 K). Sleep was assessed at baseline and follow-up at week 8, 16, and 24, using the proxy-rated
Sleep Disorder Inventory (SDI) and actigraphy (Actiwatch II, Philips Respironics). Mixed linear models were used to
evaluate intervention effects, adjusting for relevant covariates such as age, gender, number of drugs, severity of
dementia, eye disease, and estimated light exposure.
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Results: Sleep as measured by the SDI was significantly improved in the intervention group compared to the
control group from baseline to week 16 (B = − 0.06, 95% CI -0.11 - -0.01, p < .05) and from baseline to week 24 (B =
− 0.05, 95% CI -0.10 - -0.01, p < .05). There was no effect according to the SDI at week 8 and no significant effects in
terms of actigraphically measured sleep.
Conclusions: Proxy-rated sleep improved among nursing home patients with dementia following 16 and 24 weeks
of BLT. These improvements were not corroborated by actigraphy recordings.
Trial registration: ClinicalTrials.gov Identifier: NCT03357328. Registered 29 November 2017 – Retrospectively
registered.
Keywords: Sleep, Dementia, Nursing home, Actigraphy, Sleep disorder inventory
Background
Dementia denotes a group of disorders characterised by
progressive neurodegenerative and/or vascular damage,
with accompanying impairments of cognition and distur-
bances of mood and behaviour [1]. These disorders con-
stitute a severe burden at the individual and societal
level [2], making them a social health priority of the
World Health Organization [3].
Disrupted sleep constitutes a major challenge in rela-
tion to dementia, as it affects up to 70% of the patients
[4]. As sleep is essential for normal functioning, its dis-
ruption may have severe negative effects on cognitive,
emotional, and physical functioning [5]. In the context
of cognitive impairment, sleep disruption places a sig-
nificant burden on caregivers [6]. Related events such as
night-time wandering and confusion may increase the
risk of falls and injuries [7, 8]. Importantly, sleep prob-
lems are associated with increased depressive symptoms
[9–11], reduced functional status (ability to perform nor-
mal daily activities) [12], and cognitive decline [13]. Due
to limited staff in nursing homes, pharmacological treat-
ment (e.g., antidepressants, benzodiazepines, z-
hypnotics, and antipsychotics) are often resorted to for
relieving sleep disturbances [14]. Medications are, how-
ever, often associated with side-effects such as sedation
and risk of falling [14, 15], and there is generally limited
evidence for their efficacy in these populations [16].
Thus, identifying safe and effective treatments for dis-
turbed sleep is of crucial importance.
As dementia progresses, brain systems involved in
sleep-wake regulation are increasingly affected [5, 17].
Importantly, this includes neurodegeneration of the
suprachiasmatic nucleus (SCN) of the hypothalamus, the
main circadian pacemaker, which generates 24-h
rhythms in hormone levels, body temperature, and
sleep-wake behaviour. As a result, people with dementia
often display a fragmented sleep pattern with several
sleep and wake periods occurring throughout the 24-h
day [17, 18]. Disrupted sleep may be further worsened
by factors such as reduced social interaction, inactivity,
and medications [19, 20]. In addition, light exposure
plays a major role in circadian regulation, and insuffi-
cient exposure has consequently been associated with
sleep problems in dementia patients [21, 22].
Light is detected by the intrinsically photosensitive ret-
inal ganglion cells of the eye (ipRGCs; neurons in the
retina containing the light sensitive photopigment mela-
nopsin) and relayed directly to the SCN. The effects of
light exposure on the circadian system depend on the
timing, duration, illumination level (lux), and spectral
composition (i.e., the colour of the light), as well as light
exposure history [23]. The ipRGCs are maximally sensi-
tive to short wavelengths (~ 480 nm) [24, 25], hence
polychromatic light with high amounts of short wave-
lengths, i.e., blue light, therefore elicits stronger circa-
dian responses than light with large amounts of long
wavelengths (red-yellow) [26, 27]. The colour appear-
ance of light is defined by correlated colour temperature
(CCT), measured in Kelvin (K). Daylight has a large
amount of blue light, with a CCT of about 5700–7700 K,
depending on atmospheric conditions [28]. In compari-
son, standard light bulbs typically deliver more yellow
light, with lower CCT (2700–3000 K).
With increasing age, lens yellowing and excessive pupil
constriction (senescent miosis) reduce the amount of
light reaching the retina [29, 30]. Although some evi-
dence has suggested compensatory mechanisms preserv-
ing light sensitivity [31], lens yellowing has been
associated with self-reported sleep disturbances [32].
Further, Alzheimer’s disease is associated with several
pathological changes in the visual system, including loss
of ipRGCs [33]. Several studies have reported light levels
in nursing homes far below what is considered necessary
for circadian entrainment (synchronising of an organ-
isms’ rhythms to recurring environmental cues) [17, 34–
37]. For example, in a study of seven nursing homes in
the Netherlands, Sinoo et al. [37] found that 65–96% of
the light measurements fell below 750 lx. In a recent
study including 15 Norwegian dementia unit living
rooms [38], median vertical illumination was below 300
lx, even in summer. In contrast, daylight ranges from
6500 to 130,000 lx depending on weather conditions [39,
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40]. In sum, age and dementia-related changes to the
eye and low indoor illumination in relevant institutions
suggest that dementia patients are rarely exposed to light
levels sufficient to entrain the circadian clock. Therefore,
increasing light exposure, i.e., bright light treatment
(BLT), constitutes a promising non-pharmacological
treatment for disrupted sleep in people with dementia.
Traditionally, BLT has been administered using light
boxes with high illumination white light (2500–10,000 lx
at distances from 10 to 50 cm) for 30 to 120 min each
day. This requires the patient to sit relatively still and
face the box. Several studies have reported within-group
improvements of sleep outcomes using this type of BLT
[41–47], although the results are not consistent [48–50].
An issue with light boxes is that dementia patients are in
need of continuous supervision to receive sufficient light
exposure [42], which is often too demanding for the
staff. Recent advances in light emitting diode (LED)
technology have allowed for the manipulation of both
light illumination and its spectral composition. This
technology is able to deliver light of high CCT and illu-
mination and may be used to change the ambient light
of entire rooms. Researchers have in this realm typically
used light ranging from 6500 K and 1200 lx to 13,000 K
and 400 lx [51]. By this way of administering light, the
patients may move around freely, and the need for staff
to ensure treatment adherence is eliminated. In addition,
such systems may be programmed to provide light con-
trasts between midday (high illumination short wave-
length light) and early mornings and evenings (lower
illumination and “warmer”, longer wavelength light).
Although BLT has been evaluated as a treatment for sleep
problems and emotional and behavioural symptoms in de-
mentia populations for two decades, conclusive results about
its efficacy are lacking. Recent meta-analyses, with 6 to 11
studies included, have reported only small effects (Hedges’ g
of 0.25–0.30) of BLT in dementia [52, 53]. Generally, few
randomised controlled trials have been conducted and there
are considerable variations in methods and designs, such as
the timing, duration, and means of delivering BLT. Hence,
there is a need for more high-quality studies [51].
In the present study we report the primary outcomes
from the DEM.LIGHT trial aiming to evaluate the ef-
fects of a ceiling-mounted dynamic ambient BLT solu-
tion on sleep in nursing home patients with severe
dementia. We hypothesised that the BLT condition
would improve sleep measured by actigraphy and a
proxy-rated sleep scale across the 24-week treatment
period, as compared to a control group receiving con-
ventional light with standard and constant light levels.
Methods
The present paper is based on data from the 24-week
cluster randomised placebo-controlled trial “Therapy
Light Rooms for Nursing Home Patients with Dementia–
Designing Diurnal Conditions for Improved Sleep, Mood
and Behavioural Problems”, the DEM.LIGHT trial
(ClinicalTrials.gov Identifier: NCT03357328). This trial
evaluated the effect of a BLT solution on sleep, circadian
rhythmicity, mood, behaviour, and function in nursing
home patients with dementia. The present paper reports
on the sleep outcomes of the DEM.LIGHT trial. The
other outcomes will be reported in subsequent papers.
The DEM.LIGHT trial was conducted from late Septem-
ber 2017 to early April 2018, in Bergen, Norway (60°3’N,
5°3’E). The intervention period lasted for 24 weeks and
data were collected at baseline, week 8, week 16, and
week 24. The present study adheres to the CONSORT
guidelines [54].
Participants
The Department of Health and Care, City of Bergen,
Norway, supported the study by providing information
about eligible nursing home dementia units (i.e., nursing
homes not involved in other trials or quality of care pro-
jects, and where ceiling light instalment was possible).
The management of eligible nursing homes was con-
tacted by the two researchers leading the data collec-
tion (GJH, EK). Site visits were conducted to provide
information about the study and assess if light instal-
ment was possible. In total, 14 nursing homes were
approached, of which 8 units from eight nursing homes
were included. Nursing home units and patients were re-
cruited between September 2016 and August 2017. The
eligibility criteria were discussed with the resident med-
ical practitioner of each nursing home before all the eli-
gible patients at the unit were invited to participate.
Inclusion criteria were as follows: The patient had to be
60 years of age or older, in long-term care (> 4 weeks),
have dementia in accordance with DSM-5 criteria and
either sleep/circadian rhythm disturbances, BPSD, or se-
verely reduced activities of daily living. Exclusion criteria
were blindness or other reasons the patient was unable
to benefit from light; the patient was taking part in an-
other trial; a condition that contra-indicated the inter-
vention; an advanced, severe medical condition and/or
expected survival of less than 6 months; psychosis or a
severe mental disorder; or other aspects that could inter-
fere with participation. Due to the long follow-up of 6
months, it was not possible to maintain stable doses of
medications during the course of the study. The number
of psychotropic medications were, however, controlled
for in the analyses.
Procedures
The intervention
A LED ceiling-mounted bright light solution, delivered
by Glamox AS (supplier of professional lighting
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solutions), was installed in the common rooms of the
four intervention units. Glamox engineers calculated the
number of LED units needed in each common room
(Glamox, 1 x C95 48 CCT 6500 K MP 47W / 4702 lm),
accounting for the number and direction of windows.
The light panels were programmed to provide a cycle of
gradually higher illumination and CCT during the day
and then lower illumination and CCT in the evening
(see Fig. 1), with the highest light levels of 1000 vertical
lux and 6000 K from 10:00 to 15:00. The light equipment
was installed prior to the start of the study and light
levels were maintained at standard levels (approximately
100 lx and 3000 K) before the study commenced so that
staff and participants were familiarised with the new
light units. The intervention light sequence was activated
following baseline data collection. The control panel for
the light was locked with a personal identification num-
ber only known to the researchers. The contact informa-
tion of the researchers was provided in case of any
problems with the light setup.
The placebo control condition was created by re-
placing the light bulbs in the existing fittings with con-
ventional 3000 K light bulbs in all common rooms (CFL
AURA UNIQUE-D/E LL 18W/830 G241–2 in three
common rooms and CFL AURA UNIQUE-L LL 18W/
830 2G11 in one), thus largely maintaining the pre-
existing light levels in these units. These light bulbs were
installed immediately following the baseline data collec-
tion. After the intervention was activated and the pla-
cebo lights were installed, the daytime light levels were
measured by the researchers in all eight common rooms
using the GL Spectis 1.0 T Flicker spectrometer (GL
Optic). Spectral analysis was performed in GL Spectro-
soft. Vertical measurements were recorded to approxi-
mate corneal illumination (120 cm above the floor), and
horizontal measurements were recorded at the typical
height of reading or other visual tasks (80 cm above the
floor). Effective illuminances were calculated according
to the α-opic illuminance model using the irradiance
toolbox by Lucas et al. [55].
Outcomes
All questionnaires used in the present study were com-
pleted by daytime nursing staff that knew the patients
well, i.e., regular staff working directly with the patients.
Research staff involved in the DEM.LIGHT trial guided
the nurses in using the assessment tools. The question-
naires were completed once at each data collection time
point: either the same week the patients wore the acti-
graphs or the following week. Data regarding sociode-
mographic characteristics, diagnoses, and medication
status were collected from medical records. One of the
researchers was granted access to extract these data
from a centralised journal system used in nursing homes
by Bergen Municipality.
Sleep outcomes
Changes in sleep parameters comprised the primary out-
come of the DEM.LIGHT trial. Sleep was proxy-rated by
the nursing staff using the Sleep Disorder Inventory
(SDI) [12]. The SDI assesses seven symptoms that are
scored in terms of frequency (0–4), severity (0–3), and
caregiver distress (0–5). The SDI total score was calcu-
lated as the sum of the products of the frequency and se-
verity ratings of each of item 1–7 (range: 0–84). The
SDI has previously been demonstrated to correspond
well to actigraphy outcomes in this population [56], as
well as in home-dwelling dementia populations [12]. A
total score of five or more indicates the presence of clin-
ically significant sleep disruption [56].
Actigraphs (Actiwatch II, Philips Respironics) were
used to provide an objective estimation of sleep. Acti-
graphs are wrist-worn devices that measure activity con-
tinuously over days or weeks [57]. In accordance with
previous studies on nursing home patients, the acti-
graphs were placed on the dominant or most mobile
wrist [58–61] as this increases the chances of detecting
movement in patients who are often immobile or lethar-
gic. Based on the activity data, each epoch was scored as
sleep or wake by the Actiware software, version 6.0.9
(Philips Respironics). The threshold for wakefulness was
Fig. 1 An illustration of the intervention light sequence. The light changed gradually across 30 min between each condition. Each nursing home
could choose if they wanted to turn the lights off or to maintain 100 lx and 2500 K throughout the night (21:00–07:00). The patients generally did
not spend time in the common room during the night, and whether or not the light was on in the common room depended on the needs of
the staff during the night
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set to medium and epoch length to 1 min, as recom-
mended by Camargos et al. [61].
Determining the true bedtime and wake-time in nurs-
ing home patients is challenging, as these patients fre-
quently spend more than 12 h in bed (e.g., [58, 60]). We
initially planned to score the rest intervals based on a
predetermined scoring protocol; however, there were
rarely clear indications of bedtime and wake time, and
the nurses did not consistently press the event buttons.
Therefore, a fixed rest interval was set from 22:00 to 06:
00, in accordance with previous studies, which ensured
capturing the main sleep episode of the vast majority of
participants [22, 34, 48, 62]. A fixed daytime interval was
also set from 10:00 to 18:00. This interval corresponds
to other studies in dementia populations, and was
chosen to avoid including periods when the participants
were in bed [63]. Activity data were collected for seven
consecutive days at baseline, and at follow-up after 8, 16,
and 24 weeks. Patients had to have at least five nights of
recordings to be included in the analyses. The following
actigraph outputs were extracted: Sleep efficiency (SE;
the percentage of time spent asleep in the rest interval),
TST rest (total sleep time in the rest interval), 24-h TST,
daytime TST (TST in the daytime interval), and wake-
after-sleep-onset (WASO; the time spent awake after
sleep onset) in the rest interval. Since TST rest and SE
are perfect linear functions of each other in a fixed rest
interval, including both in the analyses would be redun-
dant and TST rest was only used as a descriptive
variable.
Other outcomes
In addition to sociodemographic data, several secondary
outcomes were used to describe the population at base-
line and as control variables in the analyses. The Mini
Mental State Examination (MMSE) assesses the level of
cognitive impairment (range: 0–30), where a low score
indicates worse cognitive function [64]. The Functional
Assessment Staging (FAST) [65] rates the severity of de-
mentia according to seven stages, where a score of 6–7
indicates severe dementia. The Charlson Comorbidity
Index (CCI) assigns weights to 17 comorbidities to as-
sess the burden of comorbid disease, where a higher
score is associated with a higher mortality risk [66]. To
assess activities of daily living (ADL), the instrument by
Lawton and Brody was used [67]. This scale includes six
items (composite score range 0–30), where a lower value
indicates better functioning and independence. The
nursing home version of the Neuropsychiatric Inventory
(NPI-NH) [68, 69] is a proxy-rated tool that assesses
“Behavioural and Psychological Symptoms of Dementia”
by assigning frequency and severity ratings to 12 symp-
toms (delusion, hallucination, agitation, depression, anx-
iety, euphoria, apathy, disinhibition, irritability, aberrant
motor behaviour, night-time behaviour and eating
disturbance).
The staff at each unit were urged to report any change
in patient health or behaviour in relation to the interven-
tion. Potential adverse events and tolerability were also
monitored at each data collection visit.
Adherence to treatment
To assess adherence to treatment, a questionnaire was
administered to the nursing staff, where they were asked
to estimate the time each patient spent in the common
room during different epochs of the day (average during
the last 8 weeks). The epochs corresponded with the
light cycle of the intervention, so that the day was split
into 07:00–10:00, 10:00–15:00, 15:00–18:00, and “after
18:00”. The nursing staff provided a time estimate for
each epoch in terms of hours and minutes. They were
also instructed to report the number of days when the
patient was not present in the common room, and in-
formed that these days should not be included in the
above-mentioned estimate. For the purpose of this study,
the time estimates corresponding to the epoch with the
highest light levels (10:00–15:00) were included in the
analyses.
Sample size and power
Expecting moderate effect sizes (Cohen’s d = .50) for the
actigraphy outcomes, a .05 alpha level (two-tailed), and
the power set to .80, the power-analysis showed that 64
participants from a minimum of 8 clusters were needed
in order to detect differences between conditions.
Expecting a 20% dropout, the aim was to recruit 80 par-
ticipants [70, 71].
Randomisation
After eight nursing home units were included, clusters
(each unit constituted one cluster) were randomised to
the intervention condition (1) or the control condition
(0) using random group assignment in SPSS. Random-
isation and enrolment were completed by the research
group.
Blinding
Although the placebo effect might not be an issue in
those with severe dementia, staff might be affected, cre-
ating bias such as the Hawthorne effect [72, 73]. Hence,
potential changes in staff routines and behaviour in re-
sponse to the treatment may affect outcomes, making a
control condition necessary. Because staff and partici-
pants could not be kept blind to the intervention, as the
light setup comprised an obvious change in the common
room, new light bulbs were fitted in the control units to
mimic an intervention and ensure similar light levels
across the control units. The participants and nursing
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staff were consequently unaware of condition assign-
ment and all included units were located at different
nursing homes to minimise threats to internal validity in
terms of performance and detection bias [74]. After the
end of the trial, the study design was explained to the
staff, who were then asked to answer a questionnaire
asking whether they thought they were in the control or
intervention group.
Statistical analyses
We initially planned to analyse data using ANOVA, but
owing to some missing data due to non-compliance to
actigraphy and because some patients passed away or
moved to another facility during the study, we evaluated
the intervention effects by means of linear mixed models
using the lme4 package in R [75, 76]. This analysis
method takes into account all available data, performs
better than alternatives when there are missing data, and
estimates fixed effects while adjusting for correlation
due to repeated measurements on each subject [77, 78].
Linear mixed models using restricted maximum likeli-
hood estimation were used to assess all outcomes.
Group (intervention vs. control), time (treated as cat-
egorical with levels baseline, 8 weeks, 16 weeks, and 24
weeks), and the group-by-time interaction were included
as fixed effects in the model. The models were fitted
with random intercepts at the patient level to account
for intra-participant correlation of the outcomes, and
random slope was included if model fit improved.
Models were selected based on best fit according to like-
lihood ratio tests.
A range of factors are likely to impact the response to
BLT, and a range of predetermined prognostic variables
were tested as covariates. AIC and BIC were examined,
and likelihood ratio tests were performed using the
Anova package in R. Furthermore, covariates that im-
proved fit were added to the model. The following list of
covariates were tested: Age, gender, number of psycho-
tropic medications, CCI-scores, FAST-scores, MMSE-
scores, eye disease, whether the patient passed away or
moved during the study (drop-out), and average time in
the common room during the day (between 10:00 and
15:00). Melanopic lux was also tested as a covariate be-
cause the light levels varied within the intervention
group (ranging from 675 to 1050 mean vertical melano-
pic lux) and control group (56 to 261 melanopic lux)
(Table S1).
Preliminary analyses showed that the SDI data were
highly skewed, consequently the scores were trans-
formed to achieve normal distribution by adding a con-
stant of 0.5 and using a Box Cox transformation, which
resulted in a lambda of 0.6.
Further, the relationship between sleep, demographic
and secondary outcomes at baseline was investigated by
using correlation analysis for continuous data and com-
paring groups for categorical data using Student’s t-test.
Differences in light levels between the intervention and
the placebo condition, as well as differences in light ex-
posure time were evaluated using Student’s t-tests and
Mann-Whitney U tests in SPSS for Windows, version 25
(IBM).
Missing data
If single questionnaires were missing data on 20% or
more of items on the SDI, they were excluded from the
analyses. For questionnaires missing less than 20%, and
where data were missing completely at random, imputa-
tions were made using expectation maximisation (EM)
in SPSS.
Results
Seventy-eight patients were evaluated for eligibility, of
which 69 were recruited to the study (see the flow chart
in Fig. 2). Figure 3 shows the number of participants in-
cluded in each analysis at each time point and reasons
for missing data (not counting data missing due to death
or moving away). Of the 69 patients who were enrolled,
the mean age was 84 years, and 68% were female. The
mean MMSE score was 6.4 (SD = 6.7) (Table 1).
Table 2 shows the mean light levels in the intervention
and control condition, respectively. All light metrics
were significantly higher in the intervention group than
the control group (all p’s < .05 and Bonferroni adjusted
p < .008). The supplemental Table S1 shows the light
measurements separately for each unit. There was some
variability in light levels across intervention units, and
one unit in particular had lower than intended vertical
illumination (722; SD = 69; photopic lux and 675; SD =
62; melanopic lux). Also, one control unit had higher il-
lumination than the other control units, with 368 (SD =
99) photopic lux and 261 (SD = 125) melanopic lux. All
other control units had between 134 and 271 photopic
lux and between 56 and 143 melanopic lux. Both hori-
zontal and vertical measurements and photopic lux, mel-
anopic lux, and CCT values are provided in Table 2 as
well as in supplementary Table S1. Across the interven-
tion period, participants in the intervention group spent
a mean of 3 h and 24min (SD = 1 h 30 min), and the
control group spent 3 h and 0min (SD = 1 h 42 min) in
the common room during the time of day with the high-
est light levels (10:00–15:00), as estimated by staff
(Table 3). There were no significant differences between
the groups regarding time spent in the common room at
any time point.
The primary outcome of this randomised controlled
trial (RCT) was sleep. The linear mixed model analyses
for actigraphically measured sleep outcomes showed no
statistically significant differences between patients who
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received BLT compared to those who received standard
light (see Table 4).
For the SDI, the regression coefficient for the time*-
group interaction, representing the group difference in
change from baseline, was −.06 (95% CI −.11 to −.01; p =
.020) at week 16 and − .05 (95% CI −.10 to −.01; p = .028)
at week 24, indicating relatively better sleep in the inter-
vention group (i.e., less disrupted sleep) than the control
group at these time points. The average number of psy-
chotropic drugs was included as a covariate in this model.
There was no significant effect at week 8 (Table 4).
Table 5 shows the means and standard deviations for
the intervention group and the control group for each
outcome at each time point, as well as medians and 25th
and 75th percentiles for non-normal data.
At baseline, none of the actigraphy sleep parameters
correlated with age, total number of drugs, number of
psychotropic drugs, number of sedatives, cognitive im-
pairment, dementia severity, or comorbidity (Table 6).
The SDI score had significant positive correlations with
the total number of medications (Spearman’s rho = .30,
p = .015) and number of psychotropic medications
(Spearman’s rho = .35, p = .004). There were no gender
differences in sleep outcomes at baseline, in either
WASO (p = .419), SE (p = .622), TST day (p = .154),
TST 24 h (p = .216), or SDI (p = .356). Patients with and
without eye disease did not differ significantly on WASO
(p = .167), TST day (p = .792), TST 24 h (p = .098) or the
SDI (p = .142). However, patients with eye disease had
significantly lower SE at night (median of 57% vs. 80%,
p = .003) than those without eye disease.
No adverse events in relation to the intervention were
reported by the staff. There was no significant deterior-
ation of sleep outcomes in the intervention group
Fig. 2 Showing the flow of participants from eligibility assessment to study completion. Note: Main cause for moving was a deterioration of
somatic health requiring the patient to live in a somatic ward
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compared to the control group. There were also no
negative outcomes in terms of mortality or BPSD other
than sleep (not published).
In the intervention group, 5 out of 19 respondents
guessed that they were in the control group, and 2 out
of 12 respondents in the control group thought that they
were in the intervention group.
Discussion
The present study found no evidence for effects on acti-
graphically measured sleep following 24 weeks of BLT.
However, compared to the control group, the
intervention group fared better from baseline to week 16
and from baseline to week 24, as measured by the
proxy-rated Sleep Disorder Inventory (SDI). For the SDI,
the observed means indicate that the median SDI scores
for the control group deteriorated from baseline to week
8 and returned to baseline levels at week 16 and 24,
while the intervention group had a slight improvement
from baseline to week 24. These differences were signifi-
cant at week 16 and 24 in the mixed linear model.
The non-significant findings of the intervention
attested to by actigraph data are in line with results
based on objective sleep data from some previous RCTs
Fig. 3 Overview of missing data and reason for missing at each data collection time point, not including those lost to follow-up
Hjetland et al. BMC Geriatrics          (2021) 21:312 Page 8 of 15
in nursing home populations [48, 49] and home-
dwelling people with dementia [79]. However, other
RCTs have shown beneficial effects of bright light on
actigraphically assessed sleep parameters [45, 80, 81]. In
a recent systematic review, we addressed several factors
that may mediate the effects of BLT [51]. Although we
endeavoured to reduce potential confounders in the
present study, some issues related to the population, ex-
posure, and assessment tools need to be taken into con-
sideration. Firstly, the difference in outcomes depended
Table 1 Descriptive statistics at baseline for the 69 patients
Control group (n = 36) Intervention group (n = 33) Whole group (n = 69)
Age (mean, SD) 82.8 (7.9) 84.3 (6.2) 83.5 (7.1)
Female (%) 61 76 68
MMSE (n = 56), median (25th–75th percentile) 3.0 (1.0–7.0) 6.0 (2.0–10.0) 4.0 (1.0–9.5)
Dementia diagnoses, n (%)
AD 20 (55.6) 18 (54.5) 38 (55.0)
VD 2 (5.6) 2 (6.0) 4 (6.0)
Mixed AD and VD 0 0 0
LBD 1 (2.8) 0 1 (1.5)
FTD 0 0 0
PD 0 0 0
Unknown dementia 10 (27.8) 11 (33.3) 21 (30.5)
Other dementia 1 (2.8) 1 (3.0) 2 (3.0)
No diagnosis* 2 (5.6) 1 (3.0) 3 (4.0)
NPI-NH total score (n = 69), median (25th–75th percentile) 12.5 (5.5–42.5) 24.0 (11.0–42.0) 21.0 (6.0–42.0)
ADL (n = 69) (mean, SD) 18.4 (4.7) 17.1 (5.1) 17.8 (4.9)
FAST (n = 67), median (25th–75th percentile) 6.0 (6.0–7.0) 6.0 (6.0–6.0) 6.0 (6.0–6.0)
CCI (n = 69), median (25th–75th percentile) 1.0 (1.0–2.0) 2.0 (1.0–2.0) 1.0 (1.0–2.0)
No. of drugs (mean, SD) 6.7 (3.0) 6.5 (2.7) 6.7 (2.8)
No. of psychotropic drugs¤, median (25th–75th percentile) 3.0 (1.3–3.8) 3.0 (2.0–4.0) 3.0 (2.0–4.0)
Any psychotropic, n (%) 34 (94%) 31 (94%) 65 (94%)
No. of sedatives§, median (25th–75th percentile) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Any sedatives, n (%) 3 (8%) 6 (18%) 9 (13%)
AD Alzheimer’s Disease, ADL Activities of Daily Living, CCI Charlson Comorbidity Index, FAST Functional Assessment Staging, FTD Frontotemporal dementia, LBD
Lewy Body dementia, MMSE Mini Mental State Examiner, NPI-NH Neuropsychiatric inventory – nursing home version, PD Parkinson’s dementia, VD
Vascular dementia
Note: Medians and the 25th and 75th percentiles are presented for non-normal data. Differences at baseline were evaluated using the Student’s t-test for
parametric data and the Mann-Whitney U test for non-parametric data (marked in italics). The Chi-square probability distribution was used to analyse
categorical data
*These patients were still included as their scores on the Mini Mental State Examination and the Functional Assessment Staging suggested moderate and severe
dementia. In addition, clinically trained researchers concluded that they with high probability suffered from dementia according to the DSM-5 criteria
¤Psychotropic drugs include all drugs coded as N in the ATC system
§Sedatives include all N05C drugs, including z-hypnotics



























p-value .001 .000 .001 .002 .000 .000
Note: Vertical lux was measured 120 cm above the floor in the middle of the room in four directions that were averaged to produce the mean vertical
illumination. Mean horizontal lux was calculated as the mean of measurements 80 cm above the floor in the middle of the room and 50 cm from the back wall.
Mean lux values were calculated for the intervention and control group by averaging the values across clusters. Differences between groups tested with
Student’s t-test
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on means of assessing sleep, with the analyses showing a
significant treatment effect for the staff-rated SDI, in
contrast to actigraphically assessed sleep. This is in line
with the findings by Blytt et al. [58], who reported a sig-
nificant discrepancy between actigraphically measured
sleep and proxy-rated sleep in nursing home patients. In
a recent publication, we found a satisfactory correspond-
ence between the SDI and actigraphy data at baseline, in
the same study population as the present study [56].
Still, actigraphy and the SDI are two very different mea-
sures of sleep, and it is possible that actigraphy was not
responsive to change to the same degree as the SDI.
Actigraphy is, at its core, a measure of activity, while the
SDI comprises clinical assessments of sleep made by
nursing home staff. Immobility during wakefulness may
be miscoded as sleep by the actigraphs, and thus subtle
changes in sleep and wakefulness may not be detected.
Actigraphy has been shown to have a high sensitivity
(ability to detect sleep) of 87–99%, albeit a low specifi-
city (ability to detect wakefulness) of 28–67% compared
to polysomnography, with lower specificity occurring
when sleep efficiency is reduced [82]. In older adults
with insomnia, Sivertsen et al. [83] found a specificity of
36%. A potentially low specificity, i.e., poor wake detec-
tion, could have impacted the outcomes of this study.
Thus, actigraphy may not have been the optimal tool to
detect wakefulness in this old, multimorbid and frail
population. Hence, the field needs better and more ac-
curate, yet feasible, objective sleep recordings in demen-
tia. One promising tool in that regard is sleep radars,
which are completely non-invasive and can collect data
about whole body movement, including respiration [84].
However, sleep radars have not been validated for use in
nursing homes or in people with dementia. The fact that
the SDI-score correlated with medication use (total
number and number of psychotropic drugs), may sug-
gest that it was clinically relevant and identified clinically
significant sleep symptoms in this population.
While using a fixed rest interval for the actigraphy
data was considered the best solution in the present
study, this comes with important caveats. Nursing home
patients may spend a substantial amount of time in bed
[58], and thus the main sleep episode may take place
partially outside the chosen interval from 22:00 to 06:00.
Importantly, shifting the timing of the main sleep epi-
sode may significantly impact the results, even though
Table 3 The median time spent in the living room between 10:00 and 15:00 for each group
Week 8 Week 16 Week 24
Mean (SD) Median (25th–75th) Mean (SD) Median (25th–75th) Mean (SD) Median (25th–75th)
Intervention 3.2 (1.8) 3.3 (1.8–5.0) 3.4 (1.8) 4.0 (2.0–5.0) 3.7 (1.6) 5.0 (2.0–5.0)
Control 3.1 (1.3) 3.0 (2.0–4.0) 2.9 (1.6) 3.0 (1.5–5.0) 2.9 (1.7) 3.0 (2.0–5.0)
p-value .560 .482 .077
Note: Differences between groups tested with Mann-Whitney U test. Time in hours
Table 4 Showing the results of the linear mixed model analyses
Variables n Nmb
obs
Baseline to week 8 Baseline to week 16 Baseline to week 24
Regression
coefficient
Std.error P CI Regression
coefficient
Std.error P CI Regression
coefficient
Std.error P CI
SEa 65 201 −0.32 3.18 .920 −6.56-
5.92
2.97 3.36 .377 −3.60-
9.55




65 194 −52.18 30.86 .093 −112.66-
8.03
−36.11 33.95 .290 −102.64-
30.43
−12.46 31.41 .692 −74.03-
49.10
TST dayc 65 201 6.65 14.03 .636 −20.84-
34.14
24.83 14.79 .096 −4.16-
53.81
21.44 14.35 .138 -6.69-
49.57
WASOd 65 201 14.42 10.43 .169 −6.03-
34.86
2.59 10.98 .814 −18.92-
24.11
20.92 10.68 .052 0.01–
41.85
SDI transe 66 213 −0.04 .02 .094 −0.09-
0.01
−0.06 .03 .020 −0.11--
0.01
− 0.05 0.02 .028 −0.10--
0.01
Note: The R package lme4 assumes an unstructured variance-covariance structure
CI confidence interval, Nmb obs Number of observations, P p-value, SDI Sleep Disorder Inventory, SE (variable) sleep efficiency, std.error standard error, trans
transformed, TST total sleep time, WASO wake after sleep onset
Note: The regression coefficients reflect the change from baseline in the intervention group compared to the control group
aEye disease included as covariate
bDrop-out included as covariate
cTotal Functional Assessment Staging score in the relevant week included as covariate
dAge included as covariate
eAverage number of psychotropic medications included as covariate
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the person’s sleep is otherwise identical. For example, if
a patient slept from 22:30–06:00 at baseline and then
shifted the sleep episode to 23:30–07:00 at follow-up,
this would according to the actigraph be interpreted as a
deterioration of sleep. The SDI is more flexible in this
regard.
Further, the somatic and mental health status of the
patients may have affected sleep and/or mobility to the
extent that it reduced discernible changes in the
actigraphy-measured sleep. In addition, there was a high
use of psychotropic drugs which combined to a high
sedative load [85]. This may have reduced mobility and
consequently affected the actigraphy data to a greater
extent than the SDI data. In addition, somatic conditions
including pain are known to reduce movement in this
population [86].
The study participants were old (mean 84 years) and
had severe dementia. As neurodegeneration increasingly
affects sleep regulatory systems and eye physiology [5,
17, 29, 30], the lack of effects on actigraphy outcomes
may indicate that the patients had limited benefit from
BLT. Hence, it is possible that people with milder de-
mentia would have benefitted more from BLT. This
should be addressed in future studies.
Another important aspect to consider is the presence
of eye disease among the participants. At baseline, those
with eye disease had worse sleep than those with no eye
disease. This variable was, however, only included in the
Table 5 Observed means and standard deviations for the groups at each time point, with medians and 25th and 76th percentiles
reported for non-normal data
Intervention group Control group
Baseline Week 8 Week 16 Week 24 Baseline Week 8 Week 16 Week 24
SE Mean (SD) 75.0 (18.6) 74.8 (14.5) 76.5 (15.7) 71.8 (18.8) 72.4 (16.3) 70.3 (15.4) 69.2 (13.4) 71.7 (15.2)













































Mean (SD) 623.3 (162.0) 623.3 (162.0) 597.7 (137.3) 626.2 (179.7) 669.2 (182.7) 655.5 (157.1) 646.2 (152.9) 664.6 (186.4)
TST
day
Mean (SD) 125.4 (70.3) 119.9 (73.0) 141.2 (100.2) 137.1 (82.3) 176.2 (93.1) 150.0 (91.5) 159.0 (90.9) 154.5 (88.6)
WASO Mean (SD) 58.8 (32.4) 65.7 (36.4) 56.3 (23.7) 75.3 (48.7) 76.3 (50.0) 73.4 (43.5) 73.6 (33.7) 71.7 (39.1)
SDI Mean (SD) 10.3 (14.9) 8.0 (8.8) 7.7 (12.3) 6.9 (10.7) 10.0 (12.8) 19.2 (21.3) 10.8 (10.5) 9.4 (10.3)


















12 (40.0) 11 (47.8) 8 (40.0) 8 (33.3) 14 (45.2) 12 (44.4) 14 (60.9) 12 (54.5)
*Sleep problems defined as sleep efficiency < 75%
SE sleep efficiency, SD standard deviation, SDI Sleep Disorder Inventory, TST total sleep time, WASO wake after sleep onset
Table 6 Showing the correlation coefficients (p-values) between the sleep variables and scores on other variables at baseline
Age No. drugs No. psychotropic No. sedatives MMSE FAST CCI
WASO −.18 −.03 .04 −.06 −.03 .01 .03
TST day −.01 −.01 .04 −.18 .04 −.05 −.05
TST 24 h .02 .05 .09 −.15 .07 −.12 −.08
SE .01 .01 .02 .01 .09 −.11 −.04
SDI −.12 .30* .35** .19 −.03 −.05 .07
Note: The significance level was set to p < .05. Italics indicate non-normal data. Any pair with non-normal data was analysed using Spearman’s rho (italics). Normal
data was analysed using Pearson correlation
CCI Charlson Comorbidity Index, FAST The Functional Assessment Staging, MMSE Mini Mental State Examination, TST total sleep time, SDI Sleep Disorder Inventory,
SE sleep efficiency, WASO wake after sleep onset
*Significant at p < .05
**Significant at p < .01
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final regression model of SE, as it affected the model fit
only for this outcome, indicating that the presence of
eye disease did not significantly influence the outcomes.
Still, the difference at baseline may suggest that the
baseline lighting was more problematic to those with im-
paired vision; however, there were too few individuals to
investigate whether this group in particular benefitted
from BLT.
Environmental factors may have confounded interven-
tion effects. One of the first studies using ceiling-
mounted light found that morning and all-day treatment
(6500 K and 500–600 lx) were associated with the great-
est amount of sleep, compared to evening treatment and
standard light [87]. However, when controlling for study
location, they found opposing effects of BLT on daytime
sleepiness in the two included nursing home units, sug-
gesting that other factors were at play. In the nursing
home context, the day-to-day routines have a fundamen-
tal impact on the patients. For example, patients are
often put to bed quite early and helped out of bed quite
late in the morning. Consequently, some patients may
end up spending more than 12 h in bed [58]. This may
cause low sleep efficiency and increase the risk of noc-
turnal wakefulness. Also, other factors such as noise and
light exposure at night are known to contribute to dis-
rupted sleep in nursing home patients [88]. Together, in-
fluences from such environmental factors might have
attenuated any positive effects of BLT in the present
study.
Because BLT only affected subjectively measured sleep,
it should be considered if this was caused by placebo-by-
proxy [89] or similar phenomena. Light is inherently vis-
ible, and it was thus impossible to create a placebo con-
dition that was identical to the intervention.
Consequently, it is possible that the nurses in the control
group realised that the new light bulbs in fact delivered
standard light levels and that placebo-by-proxy effects
only operated in the intervention group. However, if
such effects were present, they should have appeared
already in week 8. Thus, it is likely that the discrepancy
in results between the two approaches of measuring
sleep relates to the inherent differences between these
measures and not to placebo-by-proxy effects.
Limitations
The present study had some important limitations. The
results show that blinding was successful only for a mi-
nority of the staff. However, success of blinding was
assessed after revealing the design to the staff, which has
been argued to yield questionable/invalid data [54]. In
addition, the response rate among the nurses was low,
and it is possible that those who did answer the blinding
questions were more interested in the research than the
nurses who did not respond.
The exact amount of light received by each participant
was not measured. Although equipment for the purpose
of continuously measuring light exposure at eye level
(e.g., [90]) has been developed (attaching a light meter to
the head), this has limited feasibility in a dementia sam-
ple. Exposure estimations based on standardised light
meter recordings and time spent in the common room
as reported by the nurses were thus considered the best
option, although it would not correlate perfectly with
real exposure.
There was some variation in light levels across units,
where one control unit had higher mean light levels (261
melanopic lux) compared to the other control units (56–
143 melanopic lux), and one intervention unit achieved
lower-than-intended light levels (675 melanopic lux
compared to 900–1050) (Table S1). Still, there was a
minimum of a 400 melanopic lux difference between the
control unit with the highest light levels, and the inter-
vention unit with the lowest light levels, and controlling
for light levels did not impact the results.
In the present study, we implemented the intervention
only during the day in the common rooms. Hence, bed-
room lighting was not a part of the intervention. Light
exposure during the night (e.g., in bedrooms) may sig-
nificantly disrupt sleep and ensuring darkness or blue-
depleted light in the patients’ bedrooms at night could
perhaps have caused a more robust effect.
The timing of the study (September–April) was chosen
to include the dark season. Even though indoor light
levels in nursing homes are low even in sunny weather
conditions [36], there is a theoretical possibility that any
beneficial effects of daylight availability during the sum-
mer and early autumn lingered during the baseline data
collection. Similarly, the last data collection at week 24
was partially performed after the spring equinox, which
might represent a confounding variable.
Due to a higher attrition rate than anticipated and
some missing data due to non-compliance to actigraphy
(Fig. 3), we ended up with a lower number of partici-
pants than recommended by our power analysis. This
needs to be taken into consideration when interpreting
the results.
Strengths
To avoid any potential carry-over effects of BLT, we
used a parallel group design. The BLT was delivered for
a long period of time to evaluate both short-term and
long-term effects. Light levels were measured in a stan-
dardised manner and reported in the appropriate light
metric accounting for the sensitivity of the circadian sys-
tem (melanopic lux). This study demonstrated that it is
feasible to install ambient light systems in nursing
homes. Further, including dementia units from eight dif-
ferent nursing homes and using lenient inclusion criteria
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provided a representative study population and high eco-
logical validity.
Conclusion
The present findings indicate that BLT improved proxy-
rated sleep among nursing home patients with dementia
after 16 and 24 weeks of treatment compared to a con-
trol group. The lack of improvement in proxy-rated
sleep at week 8 may suggest that several weeks of expos-
ure is necessary to detect beneficial effects of BLT.
There was no evidence for an effect of BLT on actigra-
phically measured sleep. Despite the results being mixed,
there is reason to assume that BLT may be beneficial for
people with severe dementia.
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